|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300078342 |
|
最近更新日期: Date of Last Refreshed on: |
2023-12-05 17:31:40 |
|
注册时间: Date of Registration: |
2023-12-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于真核有参转录组测序解析丁氏乌蔹莓软膏治疗肛瘘术后创面的作用机制 |
|
Public title: |
Analysis of the mechanism of action of Causonis japonica Cream in treating wound after anal fistula based on eukaryotic reference transcriptome sequencing |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于真核有参转录组测序解析丁氏乌蔹莓软膏治疗肛瘘术后创面的作用机制 |
|
Scientific title: |
Analysis of the mechanism of action of Causonis japonica Cream in treating wound after anal fistula based on eukaryotic reference transcriptome sequencing |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
殷莉娜 |
研究负责人: |
郑雪平 |
|
Applicant: |
Yin Lina |
Study leader: |
Zheng Xueping |
|
申请注册联系人电话: Applicant telephone: |
+86 188 5109 2670 |
研究负责人电话:
Study leader's |
+86 138 5143 6098 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
cmdyln0905@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhengxp@njucm.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市秦淮区大明路157号南京市中医院 |
研究负责人通讯地址: |
江苏省南京市秦淮区大明路157号南京市中医院 |
|
Applicant address: |
157 Daming Road, Qinhuai District, Nanjing, Jiangsu |
Study leader's address: |
157 Daming Road, Qinhuai District, Nanjing, Jiangsu |
|
申请注册联系人邮政编码: Applicant postcode: |
210022 |
研究负责人邮政编码: Study leader's postcode: |
210022 |
|
申请人所在单位: |
南京中医药大学附属南京中医院 |
||
|
Applicant's institution: |
Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine |
||
|
研究负责人所在单位: |
南京中医药大学附属南京中医院 |
||
|
Affiliation of the Leader: |
Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2023270 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京市中医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Nanjing Traditional Chinese Medicine Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-08-25 00:00:00 | ||
|
伦理委员会联系人: |
赵学龙 |
||
|
Contact Name of the ethic committee: |
Zhao Xuelong |
||
|
伦理委员会联系地址: |
江苏省南京市秦淮区大明路157号 |
||
|
Contact Address of the ethic committee: |
157 Daming Road, Qinhuai District, Nanjing, Jiangsu |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 5227 6505 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京中医药大学附属南京中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市秦淮区大明路157号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
157 Daming Road, Qinhuai District, Nanjing, Jiangsu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
南京中医药大学附属南京中医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine |
||||||||||||||||||||||
|
研究疾病: |
肛瘘 |
||||||||||||||||||||||
|
Target disease: |
anal fistula |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
借助真核有参转录组测序找寻乌蔹莓软膏治疗肛瘘术后创面的有效靶点,试图论证氧化应激是肛瘘术后创面炎症损伤难以速愈的关键因素,乌蔹莓软膏对其有明显抑制作用,丰富乌蔹莓软膏的愈创机理 |
||||||||||||||||||||||
|
Objectives of Study: |
By means of eukaryotic transcriptome sequencing, the effective target of Causonis japonica Cream in the treatment of wounds after anal fistula surgery was sought to demonstrate that oxidative stress is the key factor that makes it difficult to heal wounds after anal fistula surgery, and that Causonis japonica Cream has a significant inhibitory effect on it, enriching the healing mechanism of Causonis japonica Cream |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合符合由2012年中华中医药学会出版的《中医肛肠科常见病诊疗指南》中肛瘘的诊断标准的患者; ②性别不限,年龄在18岁至65岁之间; ③既往无肛瘘及其他肛门外科手术史,且肛门外观及肛管直肠结构及功能完整未破坏; ④自愿受试,同意参加课题研究且签署知情同意书,并能遵循医嘱,坚持术后每天换药。 |
||||||||||||||||||||||
|
Inclusion criteria |
① Patients who meet the diagnostic criteria for anal fistula in the Guidelines for the Diagnosis and Treatment of Common Anorectal Diseases of Traditional Chinese Medicine published by the Chinese Association of Traditional Chinese Medicine in 2012; ② Gender is not limited, and the age is between 18 and 65 years old; ③ No history of anal fistula or other anal surgery, and the appearance of the anus and the structure and function of the anal canal and rectum were intact; ④ Volunteer to participate in the study and sign the informed consent, and follow the doctor's advice, adhere to daily dressing change after surgery. |
||||||||||||||||||||||
|
排除标准: |
①合并有肿瘤、结核、糖尿病、营养不良、炎症性肠病、梅毒、艾滋病等影响创面生长或愈合的相关性疾病; ②合并有心脑血管、肝、肾、血液系统等严重疾病; ③妊娠、哺乳期及月经期妇女; ④对本药使用过敏者; ⑤使用其他有可能影响研究结果的药物; ⑥正在参与多课题研究以及不愿加入本研究; ⑦不符合纳入标准,无法判断疗效或资料不全等影响疗效或安全性判断。 |
||||||||||||||||||||||
|
Exclusion criteria: |
①Complicated with tumor, tuberculosis, diabetes, malnutrition, inflammatory bowel disease, syphilis, AIDS and other diseases affecting wound growth or healing; ② Complicated with cardiovascular, cerebrovascular, liver, kidney, blood system and other serious diseases; ③ Women during pregnancy, lactation and menstruation; ④ Allergic to the use of this drug; Use of other drugs that may affect the results of the study; ⑥ are participating in multiple research topics and do not want to join this study; ⑦Does not meet the inclusion criteria, can not judge the efficacy or incomplete data affect the efficacy or safety judgment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-12-01 00:00:00至 To 2025-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-12-05 00:00:00 至 To 2025-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
使用SAS统计分析系统随机在1~24内生成一组数据,实验组为1~12,对照组为13~24,然后排序处理这些随机数,患者的编号就是随机数的秩次 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
SAS statistical analysis system was used to randomly generate a set of data within 1 ~ 24 years, the experimental group was 1 ~ 12, the control group was 13 ~ 24, and then these random numbers were sequentially processed, and the patient's number was the rank of the random number |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
实验室数据和统计设盲。 |
|
Blinding: |
The grouping information of the study data was blinded and submitted to a third party for statistical analysis. and laboratory tests performed by the third Clinical Laboratory. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后以论文形式公开数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Publish the data in the form of a paper after the research is completed. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据由CRF表格收集,制成表格后输入spss进行分析。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data was collected by CRF form and then input into spss for analysis. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |